Want to see AU:VBS full AI Analyst Report?
VBS Stock Chart & Stats
AU$0.18
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.18
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.46
Previous CloseN/A
Volume32.26K
Average Volume (3M)30.62K
Market Cap
AU$6.53M
Enterprise ValueAU$3.87M
Total Cash (Recent Filing)AU$3.52M
Total Debt (Recent Filing)AU$546.66K
Price to Earnings (P/E)3.6
Beta1.44
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding62,183,052
10 Day Avg. Volume25,711
30 Day Avg. Volume30,621
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.92
Price to Sales (P/S)0.00
P/FCF Ratio-11.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Capital StructureThe return to positive equity and moderate leverage gives VBS a stronger capital structure than in earlier periods. This provides more balance-sheet support over the next several months, although the modest asset base and continuing losses limit the durability of that improvement.
Narrower Cash BurnAlthough VBS remains cash-flow negative, the reduction in free-cash-flow burn indicates some improvement in cash discipline or funding requirements. If sustained, lower annual outflows could extend financial flexibility and reduce the pace at which the company consumes available resources.
Net Income TurnaroundThe reported swing to positive net income is a favorable change in headline profitability and could support the company if it becomes repeatable. However, revenue was zero and operating losses persisted, so the improvement currently appears dependent on non-operating items rather than stronger core trading.
Bears Say
Revenue CollapseThe decline to zero revenue shows a severe loss of commercial momentum and leaves no current operating sales base to support the business. Without a reversal, VBS has limited evidence of customer monetization, making future growth dependent on restarting revenue generation.
Persistent Operating LossesDeeply negative EBITDA and EBIT indicate that the core operation is not covering its expenses, even after the reported net-income improvement. Continued operating losses can erode equity, increase reliance on external funding, and make any recovery in profitability less durable.
Negative Cash GenerationPersistent negative operating and free cash flow means VBS is not self-funding through its operations. This weakens financial resilience over the next several months, as ongoing activity requires cash resources while reported profit is not converting into operating liquidity.
Vectus Biosystems Limited News
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.07 and its highest was AU$0.46 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Vectus Biosystems Limited’s market cap is AU$6.53M.
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Feb 19, 2027 which is in 120 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Vectus Biosystems Limited released its earnings results on Aug 30, 2026. The company reported AU$0.042 earnings per share for the quarter.
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 62,183,052 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Vectus Biosystems Limited reported an EPS of AU$0.042 in its last earnings report. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vectus Biosystems Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.89%
12-Months-Change
Fundamentals
Return on Equity
206.11%
Trailing 12-Months
Asset Growth
387.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vectus Biosystems Limited
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Technical Analysis
Acrux
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―